These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 27742998)

  • 1. Neutralization of EP217609, a new dual-action FIIa/FXa anticoagulant, by its specific antidote avidin: a phase I study.
    Gueret P; Combe S; Krezel C; Fuseau E; van Giersbergen PL; Petitou M; Neuhart E
    Eur J Clin Pharmacol; 2017 Jan; 73(1):15-28. PubMed ID: 27742998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First in man study of EP217609, a new long-acting, neutralisable parenteral antithrombotic with a dual mechanism of action.
    Gueret P; Combe S; Krezel C; Fuseau E; van Giersbergen PL; Petitou M; Neuhart E
    Eur J Clin Pharmacol; 2016 Sep; 72(9):1041-50. PubMed ID: 27259709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Specificity and selectivity profile of EP217609: a new neutralizable dual-action anticoagulant that targets thrombin and factor Xa.
    Olson ST; Swanson R; Petitou M
    Blood; 2012 Mar; 119(10):2187-95. PubMed ID: 22144183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EP217609, a neutralisable dual-action FIIa/FXa anticoagulant, with antithrombotic effects in arterial thrombosis.
    Alame G; Mangin PH; Freund M; Riehl N; Magnenat S; Petitou M; Hechler B; Gachet C
    Thromb Haemost; 2015 Feb; 113(2):385-95. PubMed ID: 25374268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. From heparin to EP217609: the long way to a new pentasaccharide-based neutralisable anticoagulant with an unprecedented pharmacological profile.
    Petitou M; Nancy-Portebois V; Dubreucq G; Motte V; Meuleman D; de Kort M; van Boeckel CA; Vogel GM; Wisse JA
    Thromb Haemost; 2009 Nov; 102(5):804-10. PubMed ID: 19888512
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reversibility of the anti-FXa activity of idrabiotaparinux (biotinylated idraparinux) by intravenous avidin infusion.
    Paty I; Trellu M; Destors JM; Cortez P; Boëlle E; Sanderink G
    J Thromb Haemost; 2010 Apr; 8(4):722-9. PubMed ID: 20088937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversible biotinylated oligosaccharides: a new approach for a better management of anticoagulant therapy.
    Savi P; Herault JP; Duchaussoy P; Millet L; Schaeffer P; Petitou M; Bono F; Herbert JM
    J Thromb Haemost; 2008 Oct; 6(10):1697-706. PubMed ID: 18647228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EP42675, a synthetic parenteral dual-action anticoagulant: pharmacokinetics, pharmacodynamics, and absence of interactions with antiplatelet drugs.
    Gueret P; Krezel C; Fuseau E; van Giersbergen PL; Petitou M; Neuhart E
    J Thromb Haemost; 2014 Jan; 12(1):24-33. PubMed ID: 24237610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and pharmacodynamics of BIBT 986, a novel small molecule dual inhibitor of thrombin and factor Xa.
    Graefe-Mody EU; Schühly U; Rathgen K; Stähle H; Leitner JM; Jilma B
    J Thromb Haemost; 2006 Jul; 4(7):1502-9. PubMed ID: 16839346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of coagulation proteases Xa and IIa decreases ischemia-reperfusion injuries in a preclinical renal transplantation model.
    Tillet S; Giraud S; Kerforne T; Saint-Yves T; Joffrion S; Goujon JM; Cau J; Mauco G; Petitou M; Hauet T
    Transl Res; 2016 Dec; 178():95-106.e1. PubMed ID: 27513209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioequipotency of idraparinux and idrabiotaparinux after once weekly dosing in healthy volunteers and patients treated for acute deep vein thrombosis.
    Trellu M; Fau JB; Cortez P; Cheng S; Paty I; Boëlle E; Donat F; Sanderink GJ
    Br J Clin Pharmacol; 2013 May; 75(5):1255-64. PubMed ID: 23078631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The antithrombotic activity of EP224283, a neutralizable dual factor Xa inhibitor/glycoprotein IIbIIIa antagonist, exceeds that of the coadministered parent compounds.
    Hechler B; Freund M; Alame G; Leguay C; Gaertner S; Cazenave JP; Petitou M; Gachet C
    J Pharmacol Exp Ther; 2011 Aug; 338(2):412-20. PubMed ID: 21527535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New parenteral anticoagulants in development.
    Gómez-Outes A; Suárez-Gea ML; Lecumberri R; Rocha E; Pozo-Hernández C; Vargas-Castrillón E
    Ther Adv Cardiovasc Dis; 2011 Feb; 5(1):33-59. PubMed ID: 21045018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of idraparinux and idrabiotaparinux for anticoagulant therapy.
    Harenberg J
    Thromb Haemost; 2009 Nov; 102(5):811-5. PubMed ID: 19888513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity.
    Dyke CK; Steinhubl SR; Kleiman NS; Cannon RO; Aberle LG; Lin M; Myles SK; Melloni C; Harrington RA; Alexander JH; Becker RC; Rusconi CP
    Circulation; 2006 Dec; 114(23):2490-7. PubMed ID: 17101847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects.
    Eerenberg ES; Kamphuisen PW; Sijpkens MK; Meijers JC; Buller HR; Levi M
    Circulation; 2011 Oct; 124(14):1573-9. PubMed ID: 21900088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Crossover dose escalation study to assess safety, pharmacokinetics, and pharmacodynamics of single doses of R1663, an oral factor Xa inhibitor, in healthy male volunteers.
    Schmitt C; Pannier A; McIntyre C; Zandt H; Ciorciaro C; Winters K; Pepper T
    J Clin Pharmacol; 2012 Apr; 52(4):499-510. PubMed ID: 21566199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Andexanet alfa: a recombinant mimetic of human factor Xa for the reversal of anticoagulant therapies.
    Escolar G; Diaz-Ricart M; Arellano-Rodrigo E
    Drugs Today (Barc); 2017 May; 53(5):271-282. PubMed ID: 28650000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Andexanet: Effectively Reversing Anticoagulation.
    Lippi G; Sanchis-Gomar F; Favaloro EJ
    Trends Pharmacol Sci; 2016 Jun; 37(6):413-414. PubMed ID: 27048885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of once weekly subcutaneous idrabiotaparinux in the treatment of patients with symptomatic deep venous thrombosis.
    Equinox Investigators
    J Thromb Haemost; 2011 Jan; 9(1):92-9. PubMed ID: 20946157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.